Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 19,900 shares, a decline of 26.8% from the October 15th total of 27,200 shares. Based on an average trading volume of 11,100 shares, the short-interest ratio is presently 1.8 days. Currently, 0.6% of the shares of the stock are short sold.

Artelo Biosciences Stock Performance

Artelo Biosciences stock opened at $1.05 on Friday. Artelo Biosciences has a 52 week low of $1.00 and a 52 week high of $1.75. The stock has a market capitalization of $3.39 million, a P/E ratio of -0.37 and a beta of 1.35. The stock has a fifty day moving average of $1.15 and a 200-day moving average of $1.27.

Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, research analysts forecast that Artelo Biosciences will post -2.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ARTL. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Artelo Biosciences in a report on Wednesday. EF Hutton Acquisition Co. I upgraded shares of Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.